Literature DB >> 18997734

Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression.

Min Liu1, Noriomi Matsumura, Masaki Mandai, Kui Li, Haruhiko Yagi, Tsukasa Baba, Ayako Suzuki, Junzo Hamanishi, Ken Fukuhara, Ikuo Konishi.   

Abstract

Local immune status is influenced by the tumor microenvironment. This study aims to characterize the local immune/microenvironment status by examining tumor-infiltrating immune cells, as well as cyclooxygenase (COX) expression in tumor cells, and to analyze the relationship with the prognosis of ovarian cancers. Using immunohistochemical staining of 70 ovarian cancer specimens, the numbers of CD8+, CD57+, and CD1a+ cells infiltrating intraepithelial or stromal spaces were counted (six parameters). Hierarchical clustering was used to analyze the six parameters at one time. Expression of COX-1 and COX-2 in tumor cells was also analyzed by immunohistochemistry. Expression of both COX-1 and COX-2 was negatively correlated with intraepithelial CD8+ cells (P<0.05 for both). Hierarchical clustering using the six parameters classified ovarian cancers into three clusters. The overall and progression-free survival of cluster 1 with low CD8+ cell and high CD1a+ cell density was poorer than cluster 2 with high CD8+ cell density (P<0.05). The cluster classification did not correlate with clinical features, such as histology, stage, age, and amount of residual tumor. In a multivariate analysis, cluster 1 was an independent poor prognostic factor (P<0.05). Expression of both COX-1 and COX-2 was higher in cluster 1 than in cluster 2 (P<0.05, respectively). In conclusion, hierarchical clustering of tumor-infiltrating immune cells allows poor prognostic COX-high subgroup of ovarian cancer to be detected. COX may influence the pattern of tumor-infiltrating immune cells and prognosis in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997734     DOI: 10.1038/modpathol.2008.187

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  13 in total

Review 1.  Tumor infiltrating lymphocytes in ovarian cancer.

Authors:  Phillip P Santoiemma; Daniel J Powell
Journal:  Cancer Biol Ther       Date:  2015-04-20       Impact factor: 4.742

2.  HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes.

Authors:  Marloes Gooden; Margit Lampen; Ekaterina S Jordanova; Ninke Leffers; J Baptist Trimbos; Sjoerd H van der Burg; Hans Nijman; Thorbald van Hall
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

Review 3.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.

Authors:  Ryuma Tokunaga; Wu Zhang; Madiha Naseem; Alberto Puccini; Martin D Berger; Shivani Soni; Michelle McSkane; Hideo Baba; Heinz-Josef Lenz
Journal:  Cancer Treat Rev       Date:  2017-11-26       Impact factor: 12.111

4.  Suppression of metastatic murine ovarian cancer cells by transduced embryonic progenitor cells.

Authors:  Masaki Mandai; Junzo Hamanishi; Kaoru Abiko; Noriomi Matsumura; Tsukasa Baba; Yumiko Yoshioka; Ikuo Konishi
Journal:  Horm Cancer       Date:  2010-12       Impact factor: 3.869

5.  Menstrual cyclic change of metastin/GPR54 in endometrium.

Authors:  Tsukasa Baba; Hyun Sook Kang; Yuko Hosoe; Budiman Kharma; Kaoru Abiko; Noriomi Matsumura; Junzo Hamanishi; Ken Yamaguchi; Yumiko Yoshioka; Masafumi Koshiyama; Masaki Mandai; Susan K Murphy; Ikuo Konishi
Journal:  Med Mol Morphol       Date:  2014-06-08       Impact factor: 2.309

6.  IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.

Authors:  K Abiko; N Matsumura; J Hamanishi; N Horikawa; R Murakami; K Yamaguchi; Y Yoshioka; T Baba; I Konishi; M Mandai
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

7.  CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.

Authors:  Holger Bronger; Judith Singer; Claudia Windmüller; Ute Reuning; Daniela Zech; Claire Delbridge; Julia Dorn; Marion Kiechle; Barbara Schmalfeldt; Manfred Schmitt; Stefanie Avril
Journal:  Br J Cancer       Date:  2016-08-04       Impact factor: 7.640

8.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

Review 9.  Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.

Authors:  Alia Ghoneum; Sameh Almousa; Bailey Warren; Ammar Yasser Abdulfattah; Junjun Shu; Hebatullah Abouelfadl; Daniela Gonzalez; Christopher Livingston; Neveen Said
Journal:  Semin Cancer Biol       Date:  2021-01-18       Impact factor: 15.707

Review 10.  The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy.

Authors:  Galaxia M Rodriguez; Kristianne J C Galpin; Curtis W McCloskey; Barbara C Vanderhyden
Journal:  Cancers (Basel)       Date:  2018-07-24       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.